Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 74

1.

The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy.

Moran B, Cecil T, Chandrakumaran K, Arnold S, Mohamed F, Venkatasubramaniam A.

Colorectal Dis. 2015 Apr 16. doi: 10.1111/codi.12975. [Epub ahead of print]

PMID:
25880479
2.

A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer.

Chiva LM, Gonzalez-Martin A.

Gynecol Oncol. 2015 Jan;136(1):130-5. doi: 10.1016/j.ygyno.2014.11.072. Epub 2014 Nov 28.

PMID:
25434634
3.

Risk of definitive stoma after surgery for peritoneal malignancy in 958 patients: comparative study between complete cytoreductive surgery and maximal tumor debulking.

Riss S, Chandrakumaran K, Dayal S, Cecil TD, Mohamed F, Moran BJ.

Eur J Surg Oncol. 2015 Mar;41(3):392-5. doi: 10.1016/j.ejso.2014.09.002. Epub 2014 Sep 6.

PMID:
25238953
4.

Advances in the management of peritoneal mesothelioma.

Raza A, Huang WC, Takabe K.

World J Gastroenterol. 2014 Sep 7;20(33):11700-12. doi: 10.3748/wjg.v20.i33.11700.

5.

Peritoneal Surface Disease with Synchronous Hepatic Involvement Treated with Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

Randle RW, Doud AN, Levine EA, Clark CJ, Swett KR, Shen P, Stewart JH, Votanopoulos KI.

Ann Surg Oncol. 2015 May;22(5):1634-8. doi: 10.1245/s10434-014-3987-9. Epub 2014 Aug 14.

PMID:
25120252
6.

Cytoreduction and HIPEC after neoadjuvant chemotherapy in stage IIIC-IV ovarian cancer. Critical analysis in elderly patients.

Cascales-Campos P, Gil J, Gil E, Feliciangeli E, López V, Gonzalez AG, Ruiz-Pardo J, Nieto A, Parrilla P.

Eur J Obstet Gynecol Reprod Biol. 2014 Aug;179:88-93. doi: 10.1016/j.ejogrb.2014.05.018. Epub 2014 Jun 2.

PMID:
24965986
7.

Comparison of serial debulking and cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei of appendiceal origin.

Järvinen P, Ristimäki A, Kantonen J, Aronen M, Huuhtanen R, Järvinen H, Lepistö A.

Int J Colorectal Dis. 2014 Aug;29(8):999-1007. doi: 10.1007/s00384-014-1933-8. Epub 2014 Jun 26.

PMID:
24965858
8.

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: an emerging treatment option for advanced goblet cell tumors of the appendix.

McConnell YJ, Mack LA, Gui X, Carr NJ, Sideris L, Temple WJ, Dubé P, Chandrakumaran K, Moran BJ, Cecil TD.

Ann Surg Oncol. 2014 Jun;21(6):1975-82. doi: 10.1245/s10434-013-3469-5. Epub 2014 Jan 8.

PMID:
24398544
9.

Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.

Fagotti A, Petrillo M, Costantini B, Fanfani F, Gallotta V, Chiantera V, Turco LC, Bottoni C, Scambia G.

Gynecol Oncol. 2014 Feb;132(2):303-6. doi: 10.1016/j.ygyno.2013.12.028. Epub 2013 Dec 27.

PMID:
24378877
10.

Whole abdominopelvic radiotherapy in the palliative treatment of pseudomyxoma peritonei.

Berkovic P, van de Voorde L, De Meerleer G, Delrue L, Speleers B, Van Belle S, Vandecasteele K.

Strahlenther Onkol. 2014 Feb;190(2):223-8. doi: 10.1007/s00066-013-0470-7. Epub 2013 Dec 6.

PMID:
24306063
11.

Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved.

Dayal S, Taflampas P, Riss S, Chandrakumaran K, Cecil TD, Mohamed F, Moran BJ.

Dis Colon Rectum. 2013 Dec;56(12):1366-72. doi: 10.1097/DCR.0b013e3182a62b0d.

PMID:
24201390
12.

Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and HIPEC: preliminary results in highly selected patients.

Robella M, Vaira M, Marsanic P, Mellano A, Cinquegrana A, Sottile A, De Simone M.

Minerva Chir. 2013 Dec;68(6):551-8.

PMID:
24193287
13.

Peritoneal debulking/intraperitoneal chemotherapy-non-sarcoma.

Kelly KJ, Nash GM.

J Surg Oncol. 2014 Jan;109(1):14-22. doi: 10.1002/jso.23449. Epub 2013 Oct 24. Review.

PMID:
24166680
14.

Ovarian cancer: a brief historical overview of intraperitoneal trials.

Kwa M, Muggia F.

Ann Surg Oncol. 2014 May;21(5):1429-34. doi: 10.1245/s10434-013-3219-8. Epub 2013 Oct 1.

PMID:
24081795
15.

Intrathoracic gastric volvulus as a severe, delayed surgical complication after left subphrenic peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian cancer.

Caronna R, Sammartino P, Framarino ML, Sollazzo BM, Meniconi RL, Chirletti P.

World J Surg Oncol. 2013 Sep 23;11:239. doi: 10.1186/1477-7819-11-239.

16.

[Feasibility, morbidity and survival of surgery combined with HIPEC in the management of recurrent ovarian cancer].

Furet E, Chéreau E, Lambaudie E, Bannier M, Houvenaeghel G.

Gynecol Obstet Fertil. 2013 Sep;41(9):493-8. doi: 10.1016/j.gyobfe.2013.07.011. Epub 2013 Aug 21. French.

PMID:
23972918
17.

Feasibility of radical cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendiceal origin.

Järvinen P, Ristimäki A, Kantonen J, Lepistö A.

Scand J Surg. 2013;102(3):145-51. doi: 10.1177/1457496913490463.

PMID:
23963027
18.

FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer.

Lim B, Scicchitano A, Beachler C, Gusani N, Sarwani N, Yang Z, Staveley-O'Carroll K, Ashkenazi A, Portera C, El-Deiry WS.

Cancer Biol Ther. 2013 Aug;14(8):711-9. doi: 10.4161/cbt.25310. Epub 2013 Jun 13.

19.

Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis.

Salvatorelli E, De Tursi M, Menna P, Carella C, Massari R, Colasante A, Iacobelli S, Minotti G.

Drug Metab Dispos. 2012 Dec;40(12):2365-73. doi: 10.1124/dmd.112.047480. Epub 2012 Sep 12.

20.

Ureteral stenting in cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy as a routine procedure: evidence and necessity.

Coccolini F, Lotti M, Manfredi R, Catena F, Vallicelli C, De Iaco PA, Da Pozzo L, Frigerio L, Ansaloni L.

Urol Int. 2012;89(3):307-10. doi: 10.1159/000339920. Epub 2012 Aug 1.

PMID:
22868250
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk